Roxadustat - Astellas Pharma/AstraZeneca/FibroGen

Drug Profile

Roxadustat - Astellas Pharma/AstraZeneca/FibroGen

Alternative Names: ASP 1517; AZD 9941; FG-4592; Roxadustat

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator FibroGen
  • Developer Astellas Pharma; AstraZeneca; FibroGen
  • Class Amides; Antianaemics; Carboxylic acids; Isoquinolines; Small molecules
  • Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Anaemia
  • Discontinued Sickle cell anaemia

Most Recent Events

  • 08 Nov 2017 FibroGen plans a phase III trial for Anaemia (associated with Myelodysplastic syndrome) in USA in the fourth quarter of 2017
  • 01 Nov 2017 Astellas completes a phase III trial in Anaemia in United Kingdom, Belgium, Bulgaria, Italy, Poland, Romania, Russia, Spain, South Africa, Hungary, Greece, Belarus, Colombia, Dominican Republic, Estonia, Georgia, Guatemala, Panama, Peru, Serbia, Turkey and Ukraine (PO) (NCT01887600)
  • 31 Oct 2017 Top-line efficacy data from a phase III trial in Anaemia (In chronic kidney disease patients undergoing peritoneal dialysis) released by Astellas and FibroGen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top